TherapeuticsMD Inc (NASDAQ:TXMD) – Research analysts at Jefferies Group dropped their FY2018 earnings per share estimates for shares of TherapeuticsMD in a research note issued to investors on Tuesday. Jefferies Group analyst M. Andrews now forecasts that the company will post earnings of ($0.45) per share for the year, down from their prior estimate of ($0.40). Jefferies Group also issued estimates for TherapeuticsMD’s FY2021 earnings at $1.03 EPS and FY2022 earnings at $1.48 EPS.
TXMD has been the subject of several other reports. BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 25th. Cantor Fitzgerald restated a “buy” rating and set a $28.00 target price on shares of TherapeuticsMD in a research report on Sunday, January 7th. Zacks Investment Research lowered TherapeuticsMD from a “hold” rating to a “sell” rating in a research note on Friday, January 12th. Oppenheimer reaffirmed a “buy” rating and set a $10.00 price target on shares of TherapeuticsMD in a research note on Sunday, January 28th. Finally, Cowen reaffirmed an “outperform” rating and set a $16.00 price target (up previously from $13.00) on shares of TherapeuticsMD in a research note on Monday, November 6th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. TherapeuticsMD currently has an average rating of “Buy” and an average target price of $14.50.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its stake in shares of TherapeuticsMD by 12.0% in the 4th quarter. Bank of New York Mellon Corp now owns 28,973,668 shares of the company’s stock valued at $175,001,000 after acquiring an additional 3,095,804 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of TherapeuticsMD by 40.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,027,855 shares of the company’s stock valued at $112,783,000 after acquiring an additional 6,340,346 shares during the last quarter. BlackRock Inc. lifted its stake in shares of TherapeuticsMD by 29.7% in the 4th quarter. BlackRock Inc. now owns 14,431,862 shares of the company’s stock valued at $87,169,000 after acquiring an additional 3,307,477 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of TherapeuticsMD by 5.9% in the 4th quarter. Franklin Resources Inc. now owns 10,992,409 shares of the company’s stock valued at $66,394,000 after acquiring an additional 612,965 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of TherapeuticsMD by 4.4% in the 2nd quarter. Vanguard Group Inc. now owns 10,231,081 shares of the company’s stock valued at $53,918,000 after acquiring an additional 429,211 shares during the last quarter. 72.65% of the stock is owned by institutional investors.
In other news, Director Tommy G. Thompson purchased 5,000 shares of the company’s stock in a transaction on Friday, December 8th. The stock was purchased at an average price of $6.21 per share, with a total value of $31,050.00. Following the completion of the purchase, the director now directly owns 3,555 shares in the company, valued at approximately $22,076.55. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 23.92% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “TherapeuticsMD Inc (TXMD) to Post FY2018 Earnings of ($0.45) Per Share, Jefferies Group Forecasts” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/02/15/therapeuticsmd-inc-txmd-to-post-fy2018-earnings-of-0-45-per-share-jefferies-group-forecasts.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.